Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in targeting bacterial transcription.

Philippe Villain-Guillot1, Lionel Bastide, Maxime Gualtieri

  • 1CNRS UMR 5236, UM1 UM2, Centre d'études d'agents pathogènes et Biotechnologies our la Santé, Av Charles Flahault, 34093 Montpellier, France.

Drug Discovery Today
|March 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MexXY-OprM efflux pump mediates resistance to odilorhabdins in <i>Pseudomonas aeruginosa</i>.

Microbiology spectrum·2026
Same author

Global transcriptomics and targeted metabolite analysis reveal the involvement of the AcrAB efflux pump in physiological functions by exporting signaling molecules in <i>Photorhabdus laumondii</i>.

Microbiology spectrum·2025
Same author

In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains.

The Journal of antimicrobial chemotherapy·2025
Same author

Pharmacodynamics of NOSO-502 studied in vitro and in vivo: determination of the dominant pharmacodynamic index driver.

The Journal of antimicrobial chemotherapy·2025
Same author

The AcrAB efflux pump confers self-resistance to stilbenes in Photorhabdus laumondii.

Research in microbiology·2023
Same author

Exploring Cluster-Dependent Antibacterial Activities and Resistance Pathways of NOSO-502 and Colistin against Enterobacter cloacae Complex Species.

Antimicrobial agents and chemotherapy·2022

Bacterial RNA polymerase (RNAP) is crucial for making RNA and is targeted by antibiotics like rifampicin. Recent structural studies reveal drug-binding sites, aiding new antibiotic development for tuberculosis and other infections.

Area of Science:

  • Microbiology
  • Molecular Biology
  • Pharmacology

Background:

  • Bacterial RNA polymerase (RNAP) is a vital enzyme for transcription.
  • RNAP is a key target for antibacterial drug development.
  • Rifampicin is a highly effective anti-tuberculosis drug acting on RNAP.

Purpose of the Study:

  • To review antibiotics targeting bacterial RNAP.
  • To discuss the mechanisms of action for these drugs.
  • To explore the therapeutic potential of RNAP inhibitors.

Main Methods:

  • Review of recent structural studies on bacterial RNAP-drug complexes.
  • Analysis of molecular details of drug-binding sites.
  • Examination of the mechanisms of drug action.

Related Experiment Videos

Main Results:

  • Structural insights into bacterial RNAP drug-binding sites have been resolved.
  • Detailed understanding of how various drugs inhibit RNAP function.
  • Identification of key molecular features for drug efficacy.

Conclusions:

  • Recent structural and mechanistic studies provide a foundation for developing novel RNAP-targeting antibiotics.
  • Understanding drug-binding sites on RNAP is critical for designing new therapeutic agents.
  • Targeting bacterial RNAP remains a promising strategy for combating infectious diseases.